Trial · NCT04210843
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Half Treatment Period (52 Weeks) | STARTED | Ligelizumab 72 mg LIVI -Ligelizumab 120 mg PFS | 290 | |
| First Half Treatment Period (52 Weeks) | STARTED | Ligelizumab 120 mg LIVI -Ligelizumab 120 mg PFS | 743 | |
| First Half Treatment Period (52 Weeks) | COMPLETED | Ligelizumab 72 mg LIVI -Ligelizumab 120 mg PFS | 140 | |
| First Half Treatment Period (52 Weeks) | COMPLETED | Ligelizumab 120 mg LIVI -Ligelizumab 120 mg PFS | 369 | |
| First Half Treatment Period (52 Weeks) | NOT COMPLETED | Ligelizumab 72 mg LIVI -Ligelizumab 120 mg PFS | 150 | |
| First Half Treatment Period (52 Weeks) | NOT COMPLETED | Ligelizumab 120 mg LIVI -Ligelizumab 120 mg PFS | 374 | |
| Second Half Treatment Period (52 Weeks) | STARTED | Ligelizumab 72 mg LIVI -Ligelizumab 120 mg PFS | 77 | |
| Second Half Treatment Period (52 Weeks) | STARTED | Ligelizumab 120 mg LIVI -Ligelizumab 120 mg PFS | 206 | |
| Second Half Treatment Period (52 Weeks) | COMPLETED | Ligelizumab 72 mg LIVI -Ligelizumab 120 mg PFS | 1 | |
| Second Half Treatment Period (52 Weeks) | COMPLETED | Ligelizumab 120 mg LIVI -Ligelizumab 120 mg PFS | 2 | |
| Second Half Treatment Period (52 Weeks) | NOT COMPLETED | Ligelizumab 72 mg LIVI -Ligelizumab 120 mg PFS | 76 | |
| Second Half Treatment Period (52 Weeks) | NOT COMPLETED | Ligelizumab 120 mg LIVI -Ligelizumab 120 mg PFS | 204 | |
| Observation Period 2 (up to 52 Weeks) | STARTED | Ligelizumab 72 mg LIVI -Ligelizumab 120 mg PFS | 69 | |
| Observation Period 2 (up to 52 Weeks) | STARTED | Ligelizumab 120 mg LIVI -Ligelizumab 120 mg PFS | 201 | |
| Observation Period 2 (up to 52 Weeks) | COMPLETED | Ligelizumab 72 mg LIVI -Ligelizumab 120 mg PFS | 24 | |
| Observation Period 2 (up to 52 Weeks) | COMPLETED | Ligelizumab 120 mg LIVI -Ligelizumab 120 mg PFS | 91 | |
| Observation Period 2 (up to 52 Weeks) | NOT COMPLETED | Ligelizumab 72 mg LIVI -Ligelizumab 120 mg PFS | 45 | |
| Observation Period 2 (up to 52 Weeks) | NOT COMPLETED | Ligelizumab 120 mg LIVI -Ligelizumab 120 mg PFS | 110 | |
| Follow-up Period (up to 12 or 52 Weeks) | STARTED | Ligelizumab 72 mg LIVI -Ligelizumab 120 mg PFS | 180 | |
| Follow-up Period (up to 12 or 52 Weeks) | STARTED | Ligelizumab 120 mg LIVI -Ligelizumab 120 mg PFS | 471 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04210843/flow